Date of download: 7/11/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial Arch Intern Med. 2006;166(14): doi: /archinte Trial profile. Of the 712 patients, none met any of the following exclusion criteria: severe obstructive symptoms and signs; treatment with iodine-containing agents or medication known to affect thyroid function or thyroid iodine 131 ( 131 I) uptake (RAIU) within the last 3 months prior to inclusion; pregnancy or breastfeeding; or an acute ischemic attack within the last 3 months (owing to concern of the possible transient thyrotoxicosis after recombinant human thyrotropin stimulation). Figure Legend:

Date of download: 7/11/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial Arch Intern Med. 2006;166(14): doi: /archinte The percentage mean change in thyroid volume following stimulation with 0.3 mg of recombinant human thyrotropin or placebo 24 hours prior to iodine 131 ( 131 I) therapy. *P =.04 between groups. †P =.01 between groups. ‡P =.002 between groups. §P<.001 compared with baseline. Error bars indicate SEM. Figure Legend:

Date of download: 7/11/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial Arch Intern Med. 2006;166(14): doi: /archinte A, Correlation between goiter reduction after 1 year and initial thyroid volume (recombinant human thyrotropin group, r = −0.21 [P =.32]; placebo group, r = −0.4 [P =.02]); B, goiter reduction after 1 year and retained thyroid dose (recombinant human thyrotropin group, r = 0.14 [P =.52]; placebo group, r = 0.27 [P =.21]). To convert retained thyroid dose to gray, divide by 100. Figure Legend:

Date of download: 7/11/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial Arch Intern Med. 2006;166(14): doi: /archinte Incidence of hypothyroidism within the first year following iodine 131 ( 131 I) therapy, without and with 0.3-mg recombinant human thyrotropin prestimulation (P<.001 between groups, 1 year after treatment). Figure Legend: